ArriVent BioPharma (AVBP) Stock Price, News & Analysis

Company Overview

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Key Stats

• Today's Range: $26.95 to $27.79
• 50-Day Range: $21.01 to $31.39
• 52-Week Range: $16.10 to $32.14
• Volume: 227,483 shs
• Average Volume: 478,533 shs
• Market Capitalization: $1.29 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $43.13
• Consensus Rating: Moderate Buy

ArriVent BioPharma Stock Analysis - MarketRank™

ArriVent BioPharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 535th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ArriVent BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 2 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

ArriVent BioPharma has a consensus price target of $43.13, representing about 55.8% upside from its current price of $27.68.

Amount of Analyst Coverage

ArriVent BioPharma has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ArriVent BioPharma are expected to grow in the coming year, from ($3.78) to ($3.37) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ArriVent BioPharma is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ArriVent BioPharma is -7.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ArriVent BioPharma has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.77% of the float of ArriVent BioPharma has been sold short.

Short Interest Ratio / Days to Cover

ArriVent BioPharma has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.

Change versus previous month

Short interest in ArriVent BioPharma has recently decreased by 7.26%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ArriVent BioPharma does not currently pay a dividend.

Dividend Growth

ArriVent BioPharma does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ArriVent BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.58% of the stock of ArriVent BioPharma is held by insiders.

Percentage Held by Institutions

9.48% of the stock of ArriVent BioPharma is held by institutions.

Company Calendar

• Last Earnings: 5/11/2026
• Today: 5/26/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AVBP
• Previous Symbol: NASDAQ:AVBP
• CIK: 1868279
• Web: www.arrivent.com
• Phone: 628-277-4836
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for ArriVent BioPharma: $43.13
• High Price Target: $50.00
• Low Price Target: $33.00
• Potential Upside/Downside: +56.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.47)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$166.31 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -48.98%
• Return on Assets: -45.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.95
• Quick Ratio: 13.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.96 per share
• Price / Book: 3.95

Miscellaneous

• Outstanding Shares: 46,580,000
• Free Float: 42,579,000
• Market Cap: $1.28 billion
• Optionable: N/A
• Beta: 1.51